Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 418 for:    mesothelioma

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM) (VITMPM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02603315
Recruitment Status : Completed
First Posted : November 11, 2015
Last Update Posted : June 1, 2016
Sponsor:
Information provided by (Responsible Party):
Muna Sami Jassim, Ain Shams University

Brief Summary:
The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

Condition or disease Intervention/treatment
Malignant Pleural Mesotheliomas Other: marker CD74 and vascular endothelial growth factor VEGF

Detailed Description:
This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.

Layout table for study information
Study Type : Observational
Actual Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: To Assess the Correlation Between the Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results (Response Rate, and Overall Survival )
Study Start Date : October 2015
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mesothelioma


Intervention Details:
  • Other: marker CD74 and vascular endothelial growth factor VEGF
    correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment


Primary Outcome Measures :
  1. to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival [ Time Frame: 3-4 months ]
    The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment


Secondary Outcome Measures :
  1. assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 74 [ Time Frame: 3-4 months ]
    The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   39 Years to 84 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Egyptian patients with confirmed malignant pleural mesothelioma
Criteria

Inclusion Criteria:

  • Histopathological confirmation of malignant pleural mesothelioma .
  • Full clinical data.
  • Availability for follow up: Personal communication will be attempted in order to collect missing information.

    3-The files of all patients will be reviewed to analyze the following :

  • Operative data if done .
  • Pathological review and immunohistochemistry.
  • Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test)
  • Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\S and MRI ).
  • Treatment protocols applied: Radiotherapy and Chemotherapy.
  • Response and survival after treatment .

Exclusion Criteria:

  • cases not receive chemotherapy ,on available of evaluation after treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02603315


Locations
Layout table for location information
Egypt
Ain Shams University Hospital
Cairo, Egypt
Sponsors and Collaborators
Ain Shams University
Investigators
Layout table for investigator information
Study Director: Amr S Saad, MD Ain Shams University
Study Chair: Mahmoud Ellithy, MD Ain Shams University
Study Director: Doaa Atef, MD Ain Shams University
Study Director: Hoda Abougabal, MD Ain Shams University

Layout table for additonal information
Responsible Party: Muna Sami Jassim, Doctor in clinical oncology and nuclear medicine department, Ain Shams University
ClinicalTrials.gov Identifier: NCT02603315     History of Changes
Other Study ID Numbers: DR-81
First Posted: November 11, 2015    Key Record Dates
Last Update Posted: June 1, 2016
Last Verified: October 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial
Mitogens
Endothelial Growth Factors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Growth Substances
Physiological Effects of Drugs